



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:30
Last Report Issued 01/20/2014 13:23

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 4366SP
Patient ID 4366SP
Chain 14000174
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 14000174
Received 01/20/2014 12:32

Sample ID 14000174-001
Matrix Serum or Plasma
Patient Name 4366SP
Patient ID 4366SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

4366SP Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Teriflunomide	None Detected	ng/mL	500	
---------------	---------------	-------	-----	--

Synonym(s): Aubagio®

Teriflunomide is indicated for the treatment of patients with relapsing forms of multiple sclerosis. It takes approximately 3 months to reach steady-state concentrations.

Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL.

Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE TERIFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and teratogenicity.

Results for sample 14000174-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208

Phone: (215) 657-4900 Fax: (215) 657-2972

e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 14000174-001

Matrix Serum or Plasma

Patient Name 4366SP

Patient ID 4366SP

Collect Dt/Tm Not Given

Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
------------------------------	---------------	--------------	------------------------	--------------

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.